Charu Aggarwal, MD
Hematology & Oncology · Philadelphia, PANPI 1114181740
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $474,860 of the $540,913 with a category attached, or 87.8%. 36 manufacturers reported payments, led by AstraZeneca at 40.7% of the total. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $1728.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$220K
- Astrazeneca UK Limited$134K
- Sanofi$27K
- Daiichi Sankyo Inc.$18K
- Merck$17K
- Pfizer$15K
- plus $109K from 30 others
Across 158 payments — averaging $40,891 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.2M
- AstraZeneca$1.7M
- Daiichi Sankyo Inc.$608K
- Array Biopharma Inc$409K
- Macrogenics, Inc.$325K
- Incyte Corporation$113K
- plus $131K from 5 others
What the payments were for
- Consulting fees$474,86088%
- Speaking & faculty fees$34,6286%
- Travel & lodging$25,6495%
- Food & beverage$5,7481%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 121 | $220,133 |
| Astrazeneca UK Limited | 74 | $134,253 |
| Sanofi | 7 | $27,446 |
| Daiichi Sankyo Inc. | 12 | $17,762 |
| Merck | 9 | $17,020 |
| Pfizer | 9 | $15,437 |
| Eli Lilly | 16 | $11,507 |
| E.r. Squibb & Sons, L.L.C. | 1 | $9,750 |
| Bristol Myers Squibb | 8 | $8,897 |
| Genentech USA, Inc. | 3 | $8,310 |
| AbbVie | 4 | $6,999 |
| Lilly USA, LLC | 7 | $6,849 |
| Janssen Scientific Affairs, LLC | 5 | $6,210 |
| Johnson & Johnson | 4 | $6,165 |
| Blueprint Medicines Corporation | 3 | $5,636 |
| Immunocore Limited | 1 | $4,800 |
| Boehringer Ingelheim | 3 | $4,125 |
| Shionogi Inc | 1 | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,828 |
| Jazz Pharmaceuticals Inc. | 1 | $3,720 |
| Novocure Inc. | 2 | $3,025 |
| Foundation Medicine, Inc. | 2 | $2,750 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,247 |
| Life Technologies Corporation | 1 | $2,000 |
| Eisai Inc. | 1 | $1,875 |
| Gilead | 3 | $1,590 |
| Beigene, Ltd. | 1 | $1,430 |
| Amgen | 1 | $1,298 |
| Mirati Therapeutics, Inc. | 1 | $750 |
| Novartis | 2 | $613 |
| Seagen Inc. | 1 | $152 |
| Genmab U.S., Inc. | 2 | $148 |
| Tempus AI, Inc | 1 | $124 |
| Caris MPI, Inc. | 1 | $31 |
| Astrazeneca AB | 1 | $18 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$540,913 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
- Pierluigi PorcuPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.